Cargando…
Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651450/ https://www.ncbi.nlm.nih.gov/pubmed/37922686 http://dx.doi.org/10.1016/j.esmoop.2023.102049 |
| _version_ | 1785135999546818560 |
|---|---|
| author | Lamarca, A. Vogel, A. |
| author_facet | Lamarca, A. Vogel, A. |
| author_sort | Lamarca, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10651450 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106514502023-11-02 Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma Lamarca, A. Vogel, A. ESMO Open Editorial Elsevier 2023-11-02 /pmc/articles/PMC10651450/ /pubmed/37922686 http://dx.doi.org/10.1016/j.esmoop.2023.102049 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Editorial Lamarca, A. Vogel, A. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma |
| title | Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma |
| title_full | Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma |
| title_fullStr | Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma |
| title_full_unstemmed | Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma |
| title_short | Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma |
| title_sort | futibatinib: second ema approval for fgfr inhibitor in cholangiocarcinoma |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651450/ https://www.ncbi.nlm.nih.gov/pubmed/37922686 http://dx.doi.org/10.1016/j.esmoop.2023.102049 |
| work_keys_str_mv | AT lamarcaa futibatinibsecondemaapprovalforfgfrinhibitorincholangiocarcinoma AT vogela futibatinibsecondemaapprovalforfgfrinhibitorincholangiocarcinoma |